Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Victrelis

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Figure 4. Cost per cure for cirrhotic genotype 1 patients (by treatment regime) Hepatitis C Virus (HCV) is a global health… Expand
2014
2014
  • C. Sheridan
  • Nature Biotechnology
  • 2014
  • Corpus ID: 205265039
The US Food and Drug Administration (FDA) approvals of Gilead’s Sovaldi (sofosbuvir) on December 6 and, to a lesser extent, of… Expand
  • table 1
2013
2013
The Hepatitis C virus infects an estimated 170 million people worldwide, and is the major cause of hepatitis, cirrhosis and liver… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2012
2012
  • G. Sabourin
  • Perspective infirmiere : revue officielle de l…
  • 2012
  • Corpus ID: 2083703
 
2012
2012
Resumen Recientemente, la Agencia Europea del Medicamento ha aprobado el uso de telaprevir (Incivo ® , Janssen) y boceprevir… Expand
Review
2012
Review
2012
  • Journal de pharmacie de Belgique
  • 2012
  • Corpus ID: 37026428
 
2011
2011
Merck & Co. and Roche, two rivals in the hepatitis C virus (HCV) market, have joined forces in a broad, non-exclusive… Expand
Highly Cited
2011
Highly Cited
2011
  • C. Sheridan
  • Nature Biotechnology
  • 2011
  • Corpus ID: 205269570
for people on Victrelis-based triple therapy. But the newly approved drugs also have major shortcomings, adding an extra safety… Expand
  • table 1
2011
2011
  • K. Garber
  • Nature Biotechnology
  • 2011
  • Corpus ID: 205276296
Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral… Expand
  • figure 1
  • table 1
2011
2011
Chronic viral hepatitis B and C are a significant cause of chronic liver disease worldwide and still represent a pathology… Expand